• Decrease
  • Normal
  • Increase
U.S. Department of Health and Human Services

About FDA

FDA-TRACK Archive

The list below provides information on FDA’s performance measures and projects as aligned to FDA strategic priorities and program offices. This list enables you to view charts of performance data and progress on important projects and programs.

To view current FDA-TRACK performance measures and projects view the Active Index

Filter








Results

Number of results: 49

ItemProgramOfficeFY
Completed
Strategic PlanStrategic Goal/Area
1Improve 510(k) Submission QualityCDRHOffice of Device Evaluation2013CDRH Strategic PlanPatients in the U.S. have Access to High-Quality, Safe, and Effective Medical Devices of Public Health Importance First in the World
2Percent of CDRH employees receiving training during the monthCDRHN/A2010CDRH Strategic PlanStrengthen Our Workforce and Workplace
3Percent of OCD employees receiving training during the monthCDRHOffice of the Center Director2010CDRH Strategic PlanStrengthen Our Workforce and Workplace
4Percent of PMAPs for new CDRH employees completed on time - within 30 days of arrival (DOA) - during the monthCDRHOffice of Management Operations2012CDRH Strategic PlanStrengthen Our Workforce and Workplace
5Percent of OMO employees receiving training during the monthCDRHOffice of Management Operations2010CDRH Strategic PlanStrengthen Our Workforce and Workplace
6Percent of CDRH inter-Office eConsults completed on time during the monthCDRHAll2010CDRH Strategic PlanFully Implement a Total Product Life Cycle Approach
7Cumulative percent of CDRH 2011 Strategic Priorities actions listed in the plan completedCDRHOffice of the Center Director2012CDRH Strategic PlanCross-Cutting Measure
8Cumulative percent of CDRH FY 2010 Strategic Priorities actions listed in the plan completedCDRHOffice of the Center Director2010CDRH Strategic PlanCross-Cutting Measure
9Foster the Development of Medical Devices to Respond to Unmet Public Health NeedsCDRHOffice of the Center Director2011CDRH Strategic PlanProactively Facilitate Innovation and Address Unmet Public Health Needs
10Cumulative number of CDRH 2012 Strategic Priorities actions listed in the plan completedCDRHOffice of the Center Director2012CDRH Strategic PlanCross-Cutting Measure
11Cumulative percent of guidance documents for which a final action was taken by CDRHCDRHOffice of the Center Director2012CDRH Strategic PlanCross-Cutting Measure
12International Medical Device Regulators ForumCDRHOffice of the Center Director2012CDRH Strategic PlanFully Implement a Total Product Life Cycle Approach
13Reduce Undelivered Orders BacklogCDRHOffice of Management Operations2012CDRH Strategic PlanStrengthen Our Workforce and Workplace
14Make White Oak Facilities Assigned to CDRH More Workplace FriendlyCDRHOffice of Management Operations2011CDRH Strategic PlanStrengthen Our Workforce and Workplace
15Percent of domestic mammography facilities inspected that were free of Level 1 (serious) inspection observations during the monthCDRHOffice of Communication, Education, and Radiation Programs2012CDRH Stratgic PlanFully Implement a Total Product Life Cycle Approach
16Percent of MQSA inspections completed within the 12-14 month requirement during the monthCDRHOffice of Communication, Education, and Radiation Programs2012CDRH Stratgic PlanFully Implement a Total Product Life Cycle Approach
17Develop a Life Cycle Approach to Employee EducationCDRHOffice of Communication, Education, and Radiation Programs2012CDRH Strategic PlanStrengthen Our Workforce and Workplace
18Percent of OCER employees receiving training during the monthCDRHOffice of Communication, Education, and Radiation Programs2010CDRH Strategic PlanStrengthen Our Workforce and Workplace
19Percent of OCER inter-Office eConsults completed on time during the monthCDRHOffice of Communication, Education, and Radiation Programs2010CDRH Strategic PlanFully Implement a Total Product Life Cycle Approach
20CDRH Transparency and Decision-MakingCDRHOffice of Communication, Education, and Radiation Programs2011CDRH Strategic PlanEnhance Communication and Transparency
21Medical Device and Radiation-Emitting Product Recall Process Improvement ProjectCDRHOffice of Compliance2012CDRH Strategic PlanFully Implement a Total Product Life Cycle Approach
22CDRH 30-Day Notices completed on time, converted to 75/135-Day Supplements, or reviewed that "do not qualify as a 30-Day Notice" during the monthCDRHOffice of Compliance2012CDRH Strategic PlanFully Implement a Total Product Life Cycle Approach
23Percent of CDRH 75/135-Day Supplement decisions made in 75/135 days or less during the monthCDRHOffice of Compliance2012CDRH Strategic PlanFully Implement a Total Product Life Cycle Approach
24Percent of OC employees receiving training during the monthCDRHOffice of Compliance2010CDRH Strategic PlanStrengthen Our Workforce and Workplace
25Percent of OC inter-Office eConsults completed on time during the monthCDRHOffice of Compliance2010CDRH Strategic PlanFully Implement a Total Product Life Cycle Approach
26Compliance's Import Safety InitiativeCDRHOffice of Compliance2011CDRH Strategic PlanFully Implement a Total Product Life Cycle Approach
27Number of scientific and technical training classes led by or organized by OSEL staff during the monthCDRHOffice of Science and Engineering Laboratories2011CDRH Strategic PlanStrengthen Our Workforce and Workplace
28Number of internal and external presentations by OSEL staff during the monthCDRHOffice of Science and Engineering Laboratories2011CDRH Stratgic PlanFully Implement a Total Product Life Cycle Approach
29Percent of actions listed in OSEL research plans completed on time during the monthCDRHOffice of Science and Engineering Laboratories2011CDRH Stratgic PlanFully Implement a Total Product Life Cycle Approach
30Percent of OSEL employees receiving training during the monthCDRHOffice of Science and Engineering Laboratories2010CDRH Strategic PlanStrengthen Our Workforce and Workplace
31Percent of OSEL inter-Office eConsults completed on time during the monthCDRHOffice of Science and Engineering Laboratories2010CDRH Stratgic PlanFully Implement a Total Product Life Cycle Approach
32Average impact factor of journals in which OSEL-generated research papers were published during the monthCDRHOffice of Science and Engineering Laboratories2010CDRH Stratgic PlanFully Implement a Total Product Life Cycle Approach
33Code Sharing of Device Related SoftwareCDRHOffice of Science and Engineering Laboratories2010CDRH Strategic PlanFully Implement a Total Product Life Cycle Approach
34Electromagnetic Compatibility (EMC) of Medical DevicesCDRHOffice of Science and Engineering Laboratories2012CDRH Strategic PlanFully Implement a Total Product Life Cycle Approach
35Cumulative average number of MedSun reports submitted per hospitalCDRHOffice of Surveillance and Biometrics2012CDRH Strategic PlanFully Implement a Total Product Life Cycle Approach
36Percent of OSB employees receiving training during the monthCDRHOffice of Surveillance and Biometrics2010CDRH Strategic PlanStrengthen Our Workforce and Workplace
37Percent of OSB inter-Office eConsults completed on time during the monthCDRHOffice of Surveillance and Biometrics2010CDRH Stratgic PlanFully Implement a Total Product Life Cycle Approach
38Cumulative percent of PAS studies on publicly accessible PAS tracking website with expanded information abstracted, reviewed, and approvedCDRHOffice of Surveillance and Biometrics2010CDRH Strategic PlanFully Implement a Total Product Life Cycle Approach
39Average number of MedSun reports submitted per hospital during the monthCDRHOffice of Surveillance and Biometrics2011CDRH Strategic PlanFully Implement a Total Product Life Cycle Approach
40Percent of MedSun hospitals (in program for at least 11 months) which have submitted at least 3 reports in previous 12 monthsCDRHOffice of Surveillance and Biometrics2011CDRH Strategic PlanFully Implement a Total Product Life Cycle Approach
41Medical Device Epidemiology Network (MDEpiNET)CDRHOffice of Surveillance and Biometrics2013CDRH Strategic PlanU.S. Post-Market Surveillance Quickly Identifies Poorly Performing Devices, Accurately Characterizes Real-World Performance, and Facilitates Device Approval or Clearance
42Percent of ODE employees receiving training during the monthCDRHOffice of Device Evaluation2010CDRH Strategic PlanStrengthen Our Workforce and Workplace
43Percent of 180-day PMA supplement summary review memos posted on the web within 60 days from approval to posting during the monthCDRHOffice of Device Evaluation2012CDRH Strategic PlanFully Implement a Total Product Life Cycle Approach
44Percent of OIVD employees receiving training during the monthCDRHOffice of In Vitro Diagnostics and Radiological Health2010CDRH Strategic PlanStrengthen Our Workforce and Workplace
45Percent of 510(k) IVD decision summaries posted on the web within the 45 day timeframe during the monthCDRHOffice of In Vitro Diagnostics and Radiological Health2012CDRH Strategic PlanFully Implement a Total Product Life Cycle Approach
46Percent of ODE inter-Office eConsults completed on time during the monthCDRHOffice of Device Evaluation2010CDRH Strategic PlanFully Implement a Total Product Life Cycle Approach
47Percent of OIVD inter-Office eConsults completed on time during the monthCDRHOffice of In Vitro Diagnostics and Radiological Health2010CDRH Stratgic PlanFully Implement a Total Product Life Cycle Approach
48Cumulative percent of approved 180-day PMA supplement review memos posted during the monthCDRHOffice of Device Evaluation2010CDRH Strategic PlanFully Implement a Total Product Life Cycle Approach
49iReviewCDRHOffice of Device Evaluation2010CDRH Strategic PlanFully Implement a Total Product Life Cycle Approach

Note: The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons. In addition, FDA may change the type or amount of data provided on this website at any time. Information in the Archive Index may include measures and/or key projects for which activities are ongoing but no longer tracked as part of FDA-TRACK.